Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28179750 | 0.78 | IDO1 (0.41) | ALDH1A1TDP1TSHRKIF11RXRA | |
| SCHEMBL272815 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL450655 | 0.78 | TDP1 (0.44) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL17138351 | 0.78 | TDP1 (0.44) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL3298464 | 0.76 | ALDH1A1 (0.43) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL2102113 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL2101133 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL5000032 | 0.75 | TDP1 (0.41) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL3679277 | 0.74 | CA2 (0.39) | ALDH1A1TDP1TSHRCA2GABRA1 | |
| SCHEMBL29355273 | 0.74 | ALDH1A1 (0.63) | ALDH1A1TDP1TSHRCA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2258707-B1 | Ruthenium silyl-arene complexes, and method for production thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7880025-B2 | complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258707-A1 | Ruthenium silyl-arene complexes, and method for production thereof | Takasago International Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | SPR, LSS, SRI | ALDH1A1 2369/4885TDP1 4668/4885TSHR 4573/4885 |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | ALDH1A1 54/4885TDP1 4230/4885TSHR 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.